

Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity-Modulated Proton Therapy (IMPT)

Wei Liu, PhD

Professor

Department of Radiation Oncology

Research Director

Division of Medical Physics

Mayo Clinic Arizona

*Yang Y, Vargas CE, Bhangoo RS, Wong WW, Schild SE, Daniels TB, Keole SR, Rwigema JCM, Glass JL, Shen J, DeWees TA, Liu T, Bues M, Fatyga M, Liu W. Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity-Modulated Proton Therapy, accepted by *Int J Radiat Oncol Biol Phys*. 2021.



Disclosures

- I am a PI on a grant funded by NIH/NCI
- I am a PI on a grant funded by Arizona Department of Health Sciences (ADHS) (R01 type)
- The LET calculation software reported in this presentation has been licensed to .decimal LLC by Mayo Clinic



Outline

- Introduction of LET and RBE
 - Motivation of our study
- Dose-LET Volume Histogram (DLVH) for adverse events study in rectal bleeding
 - Study Design
 - Introduction of the tool of DLVH
 - Results
 - Clinical use of the proposed tool
- Summary




Linear Energy Transfer (LET)

- Average energy loss in a short distance (locally imparted)

$$LET = \frac{dE}{dx}$$

For protons

- Increases dramatically with the deceleration of the particles
- High at the end of the proton ranges
- Highly related to the relative biological effectiveness (RBE) of protons



However,.....

- The LET effect to patient outcome is **unclear**
- The parameters of the current RBE models have **lots of uncertainties**
- Different RBE models give **very different results**
- Current IMPT planning ignores LET information and **exclusively relies on physical dose**
- The ignorance of LET distribution may result in severe AEs and **undesirable patient outcome**
- It is important to **bypass the uncertainties** in the current RBE models, use **accurate physics quantities** like dose and LET to correlate **patient outcomes data**, and combine **dose and LET** for IMPT evaluation and treatment planning



Patient Cohort




Patient cohort: 57
Rectal bleeding: 9
Control: 48

- Aug 2016 – Sep 2017
- Conventional fractionations
- Alternating plans
- Bilateral fields
- Prostate only



Dose Volume Histogram (DVH)

Rectum






Cumulative Volume

$$V_D(d) = V(D \geq d)$$






Dose LET Volume Histogram (DLVH)

Rectum



Dose LET Volume Histogram (DLVH)

Rectum





$$V_{D,LET}(d, l) = V(D \geq d, L \geq l)$$



Dose LET Volume Histogram (DLVH)

Rectum






$$V_{D,LET}(d, l) = V(D \geq d, L \geq l)$$



Dose LET Volume Histogram (DLVH)

Rectum






$$V_{D,LET}(d, l) = V(D \geq d, L \geq l)$$







Dose LET Volume Histogram (DLVH)

Rectum



Dose LET Volume Histogram (DLVH)


Rectum



$$V_{D,LET}(d, l) = V(D \geq d, L \geq l)$$




Dose LET Volume Histogram (DLVH)




- $\text{DL}v\%$, represent the percentage **volume** of a structure that has a dose (D) of at least d Gy and an LET of at least l keV/ μm
- Present **dose** and **LET** in one plot and their interplay




Prostate patients




Dose distributions for individual fields



DLVs for individual fields




Dose LET Volume Constraints (DLVC)




DLVC1: high LET constraint

$V_{2.5 \text{ keV}/\mu\text{m}}$ at 79 Gy[RBE] to 3.2 keV/μm at 9.52 Gy[RBE]
 $< 1.27\%$ or 1.71cc

● $V(74.6 \text{ Gy[RBE]}, 2.86 \text{ keV}/\mu\text{m})$



● $V(79.4 \text{ Gy[RBE]}, 0 \text{ keV}/\mu\text{m})$





DLVC2: high dose constraint

$V_{79.4 \text{ Gy[RBE]}, 0 \text{ keV}/\mu\text{m}}$
 $< 2.23\%$ or 2.68cc



DLVC based NTCP model




Testing

Patient cohort: 21
Rectal bleeding: 8,
hyperfractionation
Control: 13

Model*	Training		Validation (Loocv)	Testing
	AUC(95%CI)	AUC(95%CI)	AUC(95%CI)	AUC(95%CI)
SVM	0.785(0.633-0.887)	0.720(0.501-0.866)	0.798(0.537-0.942)	
gEUD	0.762(0.614-0.875)	0.704(0.480-0.822)	0.779(0.441-0.950)	



Shiva: System Diagram



Shiva provide functions:


- Dose, LET, and Biological dose second check
- Interplay evaluation
- 3D/4D robust optimization
- Robust evaluation
- LET guided optimization
- SFO, MFO and IFSO
- Real-time user interaction
- Real-time on-the-fly DVH band, dose, LET, Biological dose map rendering
- Real-time point dose/LET constraint
- Dose LET Volume Histogram
- Rectum bleeding prediction
- Dose/LET engine type choice: analytical, MC2 Monte-Carlo or VPMC


In the future:

- Spot position opt



Demo: Rectum bleeding predicting






Seed Spots Analysis to Characterize Linear-Energy-Transfer (LET) Effect in the Adverse Event Regions of Head and Neck Cancer Patients Treated by Intensity-Modulated Proton Therapy (IMPT)

ORAL PRESENTATION (TU-A-TRACK 6-6) by Yang et al. on Tuesday (7/27) at 11:05AM in the session of “Outcome Modelling and Assessment” for the AAPM Virtual 63rd Annual Meeting



Summary

- Developed DLVH for LET study
- Derived DLVCs based on patient outcomes
- Established NTCP models for patient outcome prediction based on DLVCs
- Revealed both high dose and high LET effects on rectal bleeding





Acknowledgements

Postdocs and Staffs

- Yunze Yang, PhD
- Jie Shan, MS

Physicians

- Carlos E. Vargas, MD
- Ronik S. Bhangoo, MD
- William W. Wong, MD
- Steven E. Schild, MD
- Thomas B. Daniels, MD
- Sameer R. Keole, MD
- Jean-Claude M. Rwigema, MD

Medical Physicists

- Martin Bues, PhD
- Mirek Fatyga, PhD



ARIZONA DEPARTMENT
OF HEALTH SERVICES

Arizona Biomedical Research Commission

THE LAWRENCE W.
AND
MARILYN W. MATTESEN
FUND FOR CANCER RESEARCH

THE KEMPER
AND ETHEL
MARLEY
FOUNDATION

